|
Osborne, C K (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-18
|
|
Nicholson, R I; Gee, J M; Bryant, S et al. (1996) Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci 784:325-35
|
|
Osborne, C K; Coronado-Heinsohn, E B; Hilsenbeck, S G et al. (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-50
|
|
Maenpaa, J; Wiebe, V; Wurz, G et al. (1994) Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance. Cancer Chemother Pharmacol 35:149-52
|
|
Osborne, C K; Jarman, M; McCague, R et al. (1994) The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89-95
|
|
Koester, S K; Maenpaa, J U; Wiebe, V J et al. (1994) Flow cytometry: potential utility in monitoring drug effects in breast cancer. Breast Cancer Res Treat 32:57-65
|
|
Osborne, C K (1993) Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 47:83-9
|
|
Wiebe, V J; Osborne, C K; Fuqua, S A et al. (1993) Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 14:173-88
|
|
Sipila, P E; Wiebe, V J; Hubbard, G B et al. (1993) Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo. Eur J Cancer 29A:2138-44
|
|
Maenpaa, J U; Wurz, G T; Baker, W J et al. (1993) A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin. Oncol Res 5:461-6
|
Showing the most recent 10 out of 33 publications
